Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by progressive motor disability with a spectrum of non-motor symptoms. Similar to Parkinson's disease, essential tremor, dystonia, Huntington's disease, and other aging-related movement disorders are widespread in the elderly with relatively unideal medicine-treatment effects. In recent years, deep brain stimulation (DBS) has been established as an effective treatment for PD and other aging-related movement disorders, especially with motor symptoms. However, there are still many problems to be solved in research work and clinical practice in this field. For example, it is unclear regarding the most effective stimulation targets or the underlying mechanism of DBS. And it is still unknown how to choose the optimal targets among STN, GPi, PSA, VIM, etc, or if we could choose the nerve fiber for stimulation besides the nuclei, And despite wearable sensors could be a powerful tool for the digital evaluation of movement disorders or provide the feedback biomarkers for DBS, the closed-loop biomarkers for DBS are still lacking. Furthermore, apart from PD, the DBS treatment in gene-related dystonia, Huntington's disease, and other movement disorders also needs to be further explored.
This Research Topic aims to gather the latest research work and clinical practices to advance the neuromodulation treatment in Parkinson's disease and other aging-related movement disorders.
Potential topics include, but are not limited to:
- The stimulation targets (including the traditional ones, such as STN, GPI, VIM, etc., and the new ones, such as PSA, PPN, Czi, etc.) of DBS and other treatment options, as well as the underlying mechanisms
- The exploratory research of DBS in treating Huntington's disease, gene-related dystonia, and freezing gait, and its associated complications
- Networks-oriented stimulation for DBS or other neuromodulation options
- The application of wearable sensors and other new technologies for the digital evaluation of movement disorders and long-term efficacy follow-up
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by progressive motor disability with a spectrum of non-motor symptoms. Similar to Parkinson's disease, essential tremor, dystonia, Huntington's disease, and other aging-related movement disorders are widespread in the elderly with relatively unideal medicine-treatment effects. In recent years, deep brain stimulation (DBS) has been established as an effective treatment for PD and other aging-related movement disorders, especially with motor symptoms. However, there are still many problems to be solved in research work and clinical practice in this field. For example, it is unclear regarding the most effective stimulation targets or the underlying mechanism of DBS. And it is still unknown how to choose the optimal targets among STN, GPi, PSA, VIM, etc, or if we could choose the nerve fiber for stimulation besides the nuclei, And despite wearable sensors could be a powerful tool for the digital evaluation of movement disorders or provide the feedback biomarkers for DBS, the closed-loop biomarkers for DBS are still lacking. Furthermore, apart from PD, the DBS treatment in gene-related dystonia, Huntington's disease, and other movement disorders also needs to be further explored.
This Research Topic aims to gather the latest research work and clinical practices to advance the neuromodulation treatment in Parkinson's disease and other aging-related movement disorders.
Potential topics include, but are not limited to:
- The stimulation targets (including the traditional ones, such as STN, GPI, VIM, etc., and the new ones, such as PSA, PPN, Czi, etc.) of DBS and other treatment options, as well as the underlying mechanisms
- The exploratory research of DBS in treating Huntington's disease, gene-related dystonia, and freezing gait, and its associated complications
- Networks-oriented stimulation for DBS or other neuromodulation options
- The application of wearable sensors and other new technologies for the digital evaluation of movement disorders and long-term efficacy follow-up
